Significance of TP53 mutations as predictive markers of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer

X. Ma , V. Rousseau , H. Sun , Sylvie Lantuejoul , M. Filipits , R. Pirker , H. Popper , J. Mendiboure , A. L. Vataire , T. Le Chevalier , J. C. Soria , Elizabeth Brambilla , A. Dunant , P. Hainaut (1) , I. Alt-Bio Working Group

1 IPRI - International Prevention Research Institute

Adjuvant cisplatin-based chemotherapy only marginally improves survival in patients with completely resected non-small-cell lung cancer (NSCLC). We have evaluated the predictive value of mutations in TP53, encoding the tumour suppressor p53, in the International Adjuvant Lung Cancer Trial (IALT), a randomized trial of adjuvant cisplatin-based chemotherapy against observation. TP53 (exons 4-8) was sequenced in 524 archived specimens of IALT patients with a median follow-up of 7.5 years. Predictive analyses were based on Cox models adjusted for clinical and pathological variables. P-values

Domaines: Santé publique et épidémiologie

X. Ma, V. Rousseau, H. Sun, Sylvie Lantuejoul, M. Filipits, et al.. Significance of TP53 mutations as predictive markers of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer. Molecular Oncology, 2014, ⟨10.1016/j.molonc.2013.12.015⟩. ⟨hal-01262499⟩